| Biomarker ID | 443 |
| PMID | 19351846 |
| Year | 2009 |
| Biomarker | ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Androgen Dependent Vs Androgen Independent Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 10 androgen dependent and 10 androgen independednt samples were used for this analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | 80% |
| Level Of Significance | p=0.0056 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ACPP, AD-017, AMIGO2, APPBP2, ASNS, ATAD2, ATP6V0E, ATXN1, AURKB, B3GALT4, BANK1, BCAP29, BIRC5, BM039 (CENPN), BRE, BUB1, BUB1B, C18orf10, C1orf9, C22orf18 (CENPM), C5orf13, C6orf111, C6orf210, C9orf116, C9orf127, CATSPER2, CCNA2, CCNB1, CCNB2, CCNE2, CD24, CDC16, CDC2, CDC20, CDC25C, CDC6, CDC7, CDKN3, CENPA, CENPC1, CENPF, CHEK1, CHEK1, CITED2, CITED2, CLUL1, COH1, CPT2, CRADD, CTSL2, CYFIP2, DEPDC1, DGKA, DMXL1, DSCR1L1, EFNB2, ESPL1, F2R, FEN1, FLJ10036, FLJ10534, FLJ22624, GABARAPL1, GALNT7, GFPT1, GGA2, GTSE1, GTSE1, H2AFX, H2AFY, HCAP-G, HCAP-G, HECA, HMGB2, HMMR, HMMR, HPS1, IL13RA1, INSIG1, KIAA0999, KIAA1608, KIF14, KIF20A, KIF4A, KLK2, KLK2, KLK3, KNS2 KNTC2 LAMB2, LMAN1, LOC54103, MAC30, MALT1, MAPK8IP1, MCM5, MID1, MLF1IP, MLLT3, MTHFD2, MTMR1, MYCBP2, MYH10 MYRIP, NAP1L3, NAV3, NEK2, NEK2, NLGN1, NUSAP1, OIP5, OSR2, PBEF1, PCLO, PDE9A, PDIR, PER3, PIK3R1, PINK1, PIR51, PLCB4, PLK1, PMAIP1, PMS2L11, PMSCL1, PRC1, PRKWNK1, PTBP1, PTBP2, PTCD1, PTPN13, PTPRR, RAB3B, RACGAP1, RBM30, RFC3, RRM1, RRM2, RRM2, SAS, SDC2, SDC2, SDC4, SEC6L1, SHCBP1, SI, SLC29A1, SLC7A6, SMARCA2, SMC4L1, SMC4L1, SOCS2, SOD2, SOS1, Spc25, SS18, STC2, STK3, STK6, TM4SF1, TMPO, TNFRSF10B, TNFSF13, TNFSF12-TNFSF13, TWE-PRIL, TOPK, TPBG, TPX2, TRIB1, TTC3, TUBA3, TYMS, UAP1, UBE3B, USP3, VEGF, ZNF175, ZNF292, ZNF45, ZWINT |